Tanezumab in Osteoarthritis of the Hip or Knee (2)
- Conditions
- Osteoarthritis
- Interventions
- Registration Number
- NCT00863304
- Lead Sponsor
- Pfizer
- Brief Summary
Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 849
- Osteoarthritis of the hip or knee according to Kellgren-Lawrence x-ray grade of 2
- pregnancy or intent to become pregnant
- BMI greater than 39
- other severe pain, significant cardiac, neurological or psychiatric disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 tanezumab 10 mg - 2 tanezumab 5 mg - 3 naproxen - 4 placebo -
- Primary Outcome Measures
Name Time Method Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF) Baseline, Week 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 16: Baseline Observation Carried Forward (BOCF) Baseline, Week 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated maximum difficulty. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function.
Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 16: Baseline Observation Carried Forward (BOCF) Baseline, Week 16 PGA of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded on a scale ranging from 1=very good (no symptom and limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worse condition.
- Secondary Outcome Measures
Name Time Method Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Weeks 2, 4, 8, and 12: Baseline Observation Carried Forward (BOCF) Baseline, Weeks 2, 4, 8, and 12 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in Pain Subscale at Weeks 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF) Baseline, Weeks 2, 4, 8, 12, and 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 2, 4, 8 and 12: Baseline Observation Carried Forward (BOCF) Baseline, Weeks 2, 4, 8, and 12 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated maximum difficulty. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function.
Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8 and 12: Baseline Observation Carried Forward (BOCF) Baseline, Weeks 2, 4, 8, and 12 Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded on a scale ranging from 1=very good (no symptom and limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worse condition.
Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF) Baseline, Weeks 2, 4, 8, 12, and 16 Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded on a scale ranging from 1=very good (no symptom and limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worse condition.
Percentage of Participants With at Least 30 Percent and 50 Percent Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF) Weeks 2, 4, 8, 12, and 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Percentage of participants with at least 30 percent and 50 percent reduction in WOMAC pain subscale at specified weeks were reported in this outcome measure.
Percentage of Participants Who Used Rescue Medication Weeks 2, 4, 8, 12, and 16 In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication. Percentage of participants with any use of rescue medication during the specified study week were summarized.
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Baseline (Day 1) up to Week 24 An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 24 that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF) Baseline, Weeks 2, 4, 8, 12, and 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated maximum difficulty. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function.
Percentage of Participants With Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Response at Weeks 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF) Weeks 2, 4, 8, 12, and 16 Participants were considered as OMERACT-OARSI responder: if the improvement from baseline to week of interest was \>=50 percent and \>=2 units in WOMAC pain subscale or WOMAC physical function subscale score; if improvement from baseline to week of interest was \>=20 percent and \>=1 unit in at least 2 of the following: 1) WOMAC pain subscale score, 2) WOMAC physical function subscale score, 3) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 \[no pain\] to 10 \[worst possible pain\], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 \[minimum difficulty\] to 10 \[maximum difficulty\], higher score = worse physical function) and PGA of osteoarthritis (score: 1 \[very good\] to 5 \[very poor\], higher score = worse condition). Percentage of participants who were considered as OMERACT-OARSI responder were reported in this outcome measure.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF) Baseline, Weeks 2, 4, 8, 12, and 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). WOMAC pain subscale assess amount of pain experienced (score: 0 \[no pain\] to 10 \[worst possible pain\], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 \[minimum difficulty\] to 10 \[maximum difficulty\], higher score = worse physical function) and WOMAC stiffness subscale assess the amount of stiffness experienced (score: 0 \[no stiffness\] to 10 \[worst stiffness\], higher score = higher stiffness). WOMAC average score was the mean of WOMAC pain, physical function and stiffness subscale scores and ranges from 0 (no difficulty) to 10 (maximum difficulty), where higher scores indicated worse response.
Percentage of Participants With Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Response at Weeks 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF) Weeks 2, 4, 8, 12, and 16 Participants were considered as OMERACT-OARSI responder: if the improvement from baseline to week of interest was greater than or equal to (\>=) 50 percent and \>=2 units in WOMAC pain subscale or WOMAC physical function subscale score; if improvement from baseline to week of interest was \>=20 percent and \>=1 unit in at least 2 of the following: 1) WOMAC pain subscale score, 2) WOMAC physical function subscale score, 3) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 \[no pain\] to 10 \[worst possible pain\], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 \[minimum difficulty\] to 10 \[maximum difficulty\], higher score = worse physical function) and PGA of osteoarthritis (score: 1 \[very good\] to 5 \[very poor\], higher score = worse condition). Percentage of participants who were considered as OMERACT-OARSI responder were reported in this outcome measure.
Percentage of Participants With at Least 30 Percent and 50 Percent Reduction From Baseline in WOMAC Pain Subscale Score at Weeks 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF) Weeks 2, 4, 8, 12, and 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Percentage of participants with at least 30 percent and 50 percent reduction in WOMAC pain subscale at specified weeks were reported in this outcome measure.
Percentage of Participants With at Least 2 Points Improvement in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 16: Last Observation Carried Forward (LOCF) Weeks 2, 4, 8, 12, and 16 PGA of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded on a scale ranging from 1=very good (no symptom and limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worse condition. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value. Percentage of participants with improvement of at least 2 points in PGA of osteoarthritis were reported.
Percentage of Participants With Cumulative Reduction From Baseline up to Week 16 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score: Baseline Observation Carried Forward (BOCF) Baseline up to Week 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Percentage of participants with cumulative reduction (as percent) (greater than 0 percent \[%\]; \>= 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 % and 90%; = 100 %) in WOMAC pain subscale from Baseline up to Week 16 were reported.
Percentage of Participants With at Least 2 Points Improvement in Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF) Weeks 2, 4, 8, 12, and 16 PGA of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded on a scale ranging from 1=very good (no symptom and limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worse condition. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value. Percentage of participants with improvement of at least 2 points in PGA of osteoarthritis were reported.
Percentage of Participants With Cumulative Reduction From Baseline up to Week 16 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF) Baseline up to Week 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Percentage of participants with cumulative reduction (as percent) (greater than 0%; \>= 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 % and 90%; = 100 %) in WOMAC pain subscale from Baseline up to Week 16 were reported.
Change From Baseline in Average Daily Pain Score in the Index Hip or Knee at Weeks 2, 4, 8, 12, and 16: Baseline Observation Carried Forward (BOCF) Baseline, Weeks 2, 4, 8, 12, and 16 Participants assessed their average daily pain score in the index hip/knee using a scale ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicated higher pain. A weekly mean was calculated using the daily index hip/knee pain scores within each specified study week. Change from baseline was calculated using the difference between each post-baseline weekly mean and the baseline mean score.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Week 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF) Baseline, Weeks 2, 4, 8, 12, and 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip).The WOMAC stiffness subscale was a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in the index joint (knee or hip) during the past 48 hours. It was calculated as mean of the scores from 2 individual questions scored on NRS of 0 (no stiffness) to 10 (worst stiffness), where higher scores indicated higher stiffness. Total score range for WOMAC stiffness subscale score was 0 (no stiffness) to 10 (worst stiffness), where higher scores indicated higher stiffness.
Number of Participants With Abnormal Physical Examinations Findings Baseline (Day 1) Physical examination included an examination of the general appearance, skin, heart, head, eyes, ears, nose, throat, breasts, abdomen, musculoskeletal, neck, extremities, thyroid and others. Criteria for abnormal physical findings were based on investigator's discretion.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item (Pain When Walking on Flat Surface) at Weeks 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF) Baseline, Weeks 2, 4, 8, 12, and 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Participants answered a question: "How much pain have you had when walking on a flat surface?". Participants responded about the amount of pain they experienced when walking on a flat surface by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 12 and 16: Baseline Observation Carried Forward (BOCF) Baseline, Weeks 12, and 16 The SF-36 health survey is a self-administered questionnaire that measures each of the following 8 health domains: domain 1= general health, domain 2= physical function, domain 3= role physical, domain 4= bodily pain, domain 5= vitality, domain 6= social function, domain 7= role emotional, domain 8= mental health. Total score for each of the 8 domains were scaled from 0 (minimum) to 100 (maximum), where higher score indicated a better health related quality of life.
Duration of Rescue Medication Use Weeks 2, 4, 8, 12, and 16 In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication. Number of days participants used any of the rescue medication, during the specified week were summarized.
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale (Pain When Going up or Down Stairs) at Weeks 2, 4, 8, 12 and 16: Baseline Observation Carried Forward (BOCF) Baseline, Weeks 2, 4, 8, 12, and 16 WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Participants answered a question: "How much pain have you had when going up or down the stairs?" Participants responded about the amount of pain they experienced when going up or down stairs by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Number of Participants With Abnormal Electrocardiogram (ECG) Findings Baseline (Day 1) up to Week 24 All standard intervals (PR, QRS, QT, QT interval corrected for heart rate using Fridericia's formula \[QTcF\], QT interval corrected for heart rate using Bazett's formula \[QTcB\], RR intervals and heart rate) were analyzed. Participants with abnormal ECG findings reported as treatment related adverse events were presented. Relatedness to treatment was assessed by investigator.
Number of Participants With Adverse Events Associated With Vital Sign Measurements Baseline (Day 1) up to Week 24 Vital signs included the assessment of the following: body temperature, blood pressure, heart rate and respiratory rate. Number of participants with clinically significant vital signs (based on the investigator's judgment) considered as adverse events were reported.
Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Aggregate Scores at Weeks 12 and 16: Baseline Observation Carried Forward (BOCF) Baseline, Weeks 12, and 16 The SF-36 health survey is a self-administered questionnaire that measures each of the following 8 health domains: domain 1= general health, domain 2= physical function, domain 3= role physical, domain 4= bodily pain, domain 5= vitality, domain 6= social function, domain 7= role emotional, domain 8= mental health. Total score for each of the 8 domains were scaled from 0 (minimum) to 100 (maximum). These 8 domains are also summarized as 2 summary scores: mental component aggregate (MCA) and physical component aggregate (PCA). Total score range for each of the 2 summary scores =0 (minimum level of functioning) to 100 (maximum level of functioning). Higher (8 domains and 2 summary) scores indicate a better health related quality of life.
Time to Discontinuation Due to Lack of Efficacy Baseline up to Week 16 Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.
Amount of Rescue Medication Taken Weeks 2, 4, 8, 12, and 16 In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication. The total dosage of acetaminophen in mg used during the specified week were summarized.
Number of Participants With Positive Anti-Drug Antibody (ADA) Level Baseline, Weeks 8, 16, and 24 Participants who developed anti-tanezumab antibodies after treatment were evaluated for the presence of anti-tanezumab neutralizing antibodies in their serum. Number of participants with positive ADA were summarized for reporting groups: Tanezumab 5 mg + Placebo and Tanezumab 10 mg + Placebo. Results with titer value \>= 4.32 nanogram per milliliter of anti-tanezumab neutralizing antibodies were counted as positive.
Number of Participants With Laboratory Test Abnormalities Baseline (Day 1) up to Week 24 Laboratory values: hematology (hemoglobin; hematocrit; red blood cell count \[less than {\<}0.8\* lower limit of normal \[LLN\], platelets \<0.5\* LLN,\>1.75\* upper limit of normal (ULN), white blood cell count\<0.6\* LLN, \>1.5\* ULN, liver function (total bilirubin\>1.5\* ULN, aspartate aminotransferase; alanine aminotransferase; gamma-glutamyltransferase, lactate dehydrogenase, alkaline phosphatase\>3.0\* ULN, total protein; albumin\<0.8\* LLN; \>1.2\* ULN), renal function (blood urea nitrogen; creatinine\>1.3\* ULN, uric acid\>1.2\* ULN), lipids (cholesterol, triglycerides \>1.3\*ULN), electrolytes (sodium\<0.95\* LLN, \>1.05\* ULN; potassium; chloride; calcium; magnesium; phosphate; bicarbonate\<0.9\* LLN, \>1.1\* ULN), chemistry (glucose \<0.6\*LLN, \>1.5\*ULN; creatine kinase \>2.0\*ULN), urinalysis (specific gravity \<1.003, \>1.030; pH\<4.5, \>8, glucose; protein; blood; ketones; urobilinogen; bilirubin; nitrite, esterase\>=1).
Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 6, 8, 12, 16 and 24 Baseline, Weeks 2, 4, 8, 12, 16, and 24 NIS is a standardized instrument used to evaluate participant for signs of peripheral neuropathy. NIS is the sum of scores of 37 items, where 24 items scored from 0 (normal function) to 4 (extreme abnormal function), higher score indicates higher abnormality and 13 items scored from 0 (normal function) to 2 (extreme abnormal function), higher score indicates higher abnormality. NIS possible overall score ranged from 0 (no impairment) to 122 (maximum impairment), higher scores indicated increased impairment.
Trial Locations
- Locations (94)
HeartCare Research
🇺🇸Sarasota, Florida, United States
Spring Clinical Research
🇺🇸Sugar Land, Texas, United States
Sugar Land Med-Ped, P.A.
🇺🇸Sugar Land, Texas, United States
Columbus Clinical Research, Inc.
🇺🇸Columbus, Ohio, United States
Foundation for Southwest Orthopedic Research
🇺🇸Houston, Texas, United States
Clinical Research Consortium
🇺🇸Las Vegas, Nevada, United States
Wolfson Medical Center
🇺🇸Las Vegas, Nevada, United States
Providence Health Partners - Center for Clinical Research
🇺🇸Dayton, Ohio, United States
The Family Healthcare Center, PA
🇺🇸Clinton, South Carolina, United States
Low Country Rheumatology, PA
🇺🇸North Charleston, South Carolina, United States
AZ Clinical Research
🇺🇸Sugar Land, Texas, United States
South Austin Orthopedics
🇺🇸Austin, Texas, United States
Physicians' Research, Inc
🇺🇸Zanesville, Ohio, United States
Coastal Carolina Research Center
🇺🇸Mount Pleasant, South Carolina, United States
Robert R. King, M.D., PA
🇺🇸Lubbock, Texas, United States
Orthopedic & Sports Medicine Consultants
🇺🇸Middletown, Ohio, United States
Southern Orthopaedic Sports Medicine
🇺🇸Columbia, South Carolina, United States
SPRI Bronx LLC
🇺🇸Bronx, New York, United States
PrimeCare of Southeastern Ohio, Inc
🇺🇸Zanesville, Ohio, United States
Empirical Clinical Trials, LLC
🇺🇸Selah, Washington, United States
Tekton Research Inc. - Research Office
🇺🇸Austin, Texas, United States
Texas Orthopedic Specialists
🇺🇸Grapevine, Texas, United States
Arthritis Northwest, PLLC
🇺🇸Spokane, Washington, United States
Commonwealth Orthopedics & Rehabilitation , P.C.
🇺🇸Arlington, Virginia, United States
The Carolina Center for Rheumatology and Arthritis Care, PA
🇺🇸Rock Hill, South Carolina, United States
Grayline Clinical Drug Trials
🇺🇸Wichita Falls, Texas, United States
HypotheTest, LLC
🇺🇸Roanoke, Virginia, United States
Gill Orthopedic Center
🇺🇸Lubbock, Texas, United States
Central Phoenix Medical - Clinical Research Advantage
🇺🇸Phoenix, Arizona, United States
J. Lewis Research, Inc. / Foothill Family Clinic
🇺🇸Salt Lake City, Utah, United States
Cor Clinical Research, LLC
🇺🇸Oklahoma City, Oklahoma, United States
Greystone Medical Research, LLC
🇺🇸Birmingham, Alabama, United States
Denver Internal Medicine Group
🇺🇸Denver, Colorado, United States
Mountain View Clinical Research, Inc.
🇺🇸Denver, Colorado, United States
Tampa Medical Group PA
🇺🇸Tampa, Florida, United States
Saadat Ansari, MD
🇺🇸Huntsville, Alabama, United States
Clinical Research Advantage, Inc.
🇺🇸Mesa, Arizona, United States
Coastal Clinical Research, Inc.
🇺🇸Mobile, Alabama, United States
Novara Clinical Research
🇺🇸Mesa, Arizona, United States
Paradigm Clinical, Inc
🇺🇸Tucson, Arizona, United States
eStudySite
🇺🇸Chula Vista, California, United States
University Parks Hematology/Oncology
🇺🇸Englewood, California, United States
Orthopedic Physicians of Colorado, PC
🇺🇸Englewood, California, United States
Valley Research
🇺🇸Fresno, California, United States
Lakewood Orthopedic Medical & Surgical Group
🇺🇸Lakewood, California, United States
High Desert Medical Group Research for Life
🇺🇸Lancaster, California, United States
Premiere Clinical Research, LLC
🇺🇸Long Beach, California, United States
Miracle Mile Medical Center
🇺🇸Los Angeles, California, United States
Probe Clinical Research, Corp.
🇺🇸Santa Ana, California, United States
Samaritan Center for Medical Research
🇺🇸Los Gatos, California, United States
Del Carmen Medical Center
🇺🇸Reseda, California, United States
Lawrence P.McAdam, MD, A Medical Corporation
🇺🇸Thousand Oaks, California, United States
Westlake Medical Center
🇺🇸Westlake Village, California, United States
Colorado Hematology
🇺🇸Englewood, Colorado, United States
American Clinical Research, LLC
🇺🇸Englewood, Colorado, United States
Colorado Orthopedic Consultants, PC
🇺🇸Englewood, Colorado, United States
HeartCare
🇺🇸Bradenton, Florida, United States
Norwalk Medical Group
🇺🇸Norwalk, Connecticut, United States
In Vivo Clinical Research, Inc
🇺🇸Doral, Florida, United States
Rheumatology Consultants of Delaware
🇺🇸Lewes, Delaware, United States
Centre for Rheumatology, Immunology and Arthritis
🇺🇸Fort Lauderdale, Florida, United States
S & W Clinical Research
🇺🇸Fort Lauderdale, Florida, United States
Rheumatology Associates of Central Florida, PA
🇺🇸Orlando, Florida, United States
Sunshine Research Center
🇺🇸Opa-locka, Florida, United States
Masters of Clinical Research, Inc.
🇺🇸Augusta, Georgia, United States
Millennium Pain Center
🇺🇸Bloomington, Illinois, United States
Rehabilitation Institute of Chicago
🇺🇸Chicago, Illinois, United States
MediSphere Medical Research Center, LLC
🇺🇸Evansville, Indiana, United States
River Birch Research Alliance, LLC
🇺🇸Blue Ridge, Georgia, United States
Pasadena Pharmacy
🇺🇸Lexington, Kentucky, United States
Mid-Atlantic Medical Research Centers
🇺🇸Hollywood, Maryland, United States
The Pain Treatment Center of the Bluegrass
🇺🇸Lexington, Kentucky, United States
L-Marc Research Center
🇺🇸Louisville, Kentucky, United States
Gulf Coast Research, LLC
🇺🇸Baton Rouge, Louisiana, United States
Bone and Joint Clinic of Baton Rouge
🇺🇸Baton Rouge, Louisiana, United States
Miray Medical Center
🇺🇸Brockton, Massachusetts, United States
Beacon Clinical Research, LLC
🇺🇸Brockton, Massachusetts, United States
Great Lakes Research Group, Incorporated
🇺🇸Bay City, Michigan, United States
Medex Healthcare Research, Inc.
🇺🇸New York, New York, United States
St. John's Medical Research Institute, Inc.
🇺🇸Springfield, Missouri, United States
Planters Clinic
🇺🇸Port Gibson, Mississippi, United States
Diagnositc Center of Medicine
🇺🇸Henderson, Nevada, United States
Independent Clinical Researchers
🇺🇸Las Vegas, Nevada, United States
Signal Point Clinical Research Center, LLC
🇺🇸Middletown, Ohio, United States
The Neurology Center
🇺🇸Houston, Texas, United States
Southwest Orthopedic Group
🇺🇸Houston, Texas, United States
J. Lewis Research, Incorporated/Foothill Family Clinic South
🇺🇸Salt Lake City, Utah, United States
IntegraTrials, LLC
🇺🇸Arlington, Virginia, United States
Virginia Hospital Center
🇺🇸Arlington, Virginia, United States
Clinical Research Advantage, Inc. / Central Arizona Medical Associates, PC
🇺🇸Mesa, Arizona, United States
Edinger Medical Group and Research Center
🇺🇸Fountain Valley, California, United States
Peak Anesthesia and Pain Management
🇺🇸Centennial, Colorado, United States
Kendall South Medical Center, Inc
🇺🇸Miami, Florida, United States
Palmetto Clinical Trial Services, LLC
🇺🇸Simpsonville, South Carolina, United States